Lineage Cell Therapeutics
LCTX
LCTX
106 hedge funds and large institutions have $76.2M invested in Lineage Cell Therapeutics in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
1% more funds holding
Funds holding: 105 → 106 (+1)
0.17% more ownership
Funds ownership: 38.14% → 38.32% (+0.17%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Holders
106
Holding in Top 10
3
Calls
$83K
Puts
$4K
Top Buyers
| 1 | +$632K | |
| 2 | +$399K | |
| 3 | +$203K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$182K |
| 5 |
6CM
683 Capital Management
New York
|
+$151K |
Top Sellers
| 1 | -$636K | |
| 2 | -$355K | |
| 3 | -$153K | |
| 4 |
Millennium Management
New York
|
-$126K |
| 5 |
DC
Defender Capital
Charlotte,
North Carolina
|
-$106K |